Caris Life Sciences vs Lexeo Therapeutics
Caris Life Sciences vs Lexeo Therapeutics, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Caris Life Sciences is on 59/100 and Lexeo Therapeutics on 61/100.
Where each one leads
Caris Life Sciences
- agent readiness: 47/100 against 40/100
- domain rating: 63/100 against 41/100
- headcount: 1,659 against 91
- funding raised: $700M against $495M
- LinkedIn following: 77,698 against 16,654
Lexeo Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Caris Life Sciences | Lexeo Therapeutics |
|---|---|---|
| What it is | Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling. | Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases. |
| Category | Biotech, MedTech, HealthTech, Genomics | Biotech, MedTech, HealthTech, Genomics |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Platform |
| Founded | 2008 | 2020 |
| Headquarters | Irving, United States | New York City, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Caris Life Sciences | Lexeo Therapeutics |
|---|---|---|
| Employees | 1,659 | 91 |
| Total funding | $700M | $495M |
| Latest round | Series D | Public Offering |
| Valuation | $7.8B | Not published |
| LinkedIn followers | 77,698 | 16,654 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Caris Life Sciences | Lexeo Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 59/100 | 61/100 |
| Traction | 60/100 | 60/100 |
| Team | Not published | 70/100 |
| Community | Not published | 8/100 |
| Search visibility | 22/100 | 28/100 |
| Quality | 78/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (47/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 63/100 | 41/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Caris Life Sciences | Lexeo Therapeutics |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | WordPress | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Google Tag Manager | Google Tag Manager |
Caris Life Sciences vs Lexeo Therapeutics: common questions
Which is better, Caris Life Sciences or Lexeo Therapeutics?
On our 0-100 score Lexeo Therapeutics rates higher (61/100 against 59/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do Caris Life Sciences and Lexeo Therapeutics compare on the numbers?
Caris Life Sciences leads on agent readiness (47/100 against 40/100), domain rating (63/100 against 41/100), headcount (1,659 against 91), funding raised ($700M against $495M), LinkedIn following (77,698 against 16,654).
Read the full Caris Life Sciences review and pricing or the Lexeo Therapeutics review and pricing. You can also browse other Caris Life Sciences alternatives we track.